蒲地蓝消炎口服液联合利巴韦林治疗小儿手足口病Meta分析

目的系统评价蒲地蓝消炎口服液联合利巴韦林治疗小儿手足口病的临床疗效。方法检索数据库PubMed,Web of Science,Ovid,Cochrane Library,中国期刊全文数据库,万方数据库,中文科技期刊数据库,中国生物医学文献数据库。检索时间均为建库时间开始至2013年6月30日,对纳入的文献进行方法学质量评价,应用RevMan 5.0软件进行Meta分析。结果共纳入7篇随机对照研究(RCT),总样本量为1 465例,其中蒲地蓝消炎口服液联合利巴韦林治疗751例,利巴韦林组714例。蒲地蓝消炎口服液联合利巴韦林组与单用利巴韦林组的痊愈率和有效率均有显著性差异,相对危险度(RR)(95%CI)分别为1.47(1.29,1.68)与1.14(1.08,1.20);退热时间、疱疹消退时间与口腔溃疡消退时间也均差异有显著性,WMD(95%CI)分别为-1.69(-2.26,-1.13)、-1.91(-2.60,-1.23)与-1.41(-1.82,-1.00)。结论蒲地蓝消炎口服液联合利巴韦林治疗儿童手足口病疗效优于单用利巴韦林,但受纳入文献质量影响,对退热时间、疱疹消退时间与口腔溃疡消退时间影响的差异结论需要高质量的临床证据进一步证实。

Meta analysis on the efficacy of pudilan antiphlogistic oral liquid combined with ribavirin in treatment of pediatric patients with hand foot and mouth disease

Objective To systematically evaluate the effectiveness of Pudilan antiphlogistic oral liquid combined with ribavirin in treatment of pediatric patients with hand foot and mouth disease. Methods A comprehensive search was performed in the web databases including PubMed,Web of Science,Ovid,Cochrane Library,National Knowledge Infrastructure（ CNKI） of China,Wanfang Database,Chongqing VIP Database,and Chinese Biological Medicine Database（ CMB） from the establishment of data base to June 30,2013. The methodological quality of included studies was evaluated,and data analyses were performed with RevMan 5. 0 software. Results Seven papers had been searched. Among 1 465 cases,the cure rate and effective rate in Pudilan antiphlogistic oral liquid combined with ribavirin group and ribavirin group all had significant difference,and RR（ 95% CI） were 1. 47（ 1. 29,1. 68） and 1. 14（ 1. 08,1. 20） respectively. The pyretolysis time,herpes regression time and oral ulcer regression time in Pudilan antiphlogistic oral liquid combined with ribavirin group and ribavirin group had significant difference and WMD（ 95% CI） were- 1. 69（- 2. 26,- 1. 13）,- 1. 91（- 2. 60,- 1. 23） and- 1. 41（- 1. 82,- 1. 00） respectively.Conclusion The current clinical evidence has proven that the efficacy of Pudilan antiphlogistic oral liquid combined with ribavirin is better than single application of ribavirin in treatment of pediatric patients with hand foot and mouth disease,but the quality of included studies,clinical evidence of different conclusions that the influence on pyretolysis time,herpes regression time and oral ulcer regression time need further confirmation with high quality clinical evidence.